|
Functional group or structure | Toxicological studies | Application | Target site | Reference |
|
Acid-oxidized SWCNTs | Apoptosis studies showed no apparent cell toxicity | Intracellular protein transporters | Mammalian cells | Kagan et al., 2010 [52] |
Acid-treated, water-soluble SWCNTs | No changes in cell viability or structure in lysosomes and cytoplasm | | Human monocyte-derived macrophage cells | Keefer et al., 2008 [56] |
Purified COOH-SWCNTs | No cytotoxicity | Pharmacological applications | Cultured mammalian cells | Al-Jamal et al., 2012 [57] |
Oxidized ultrashort SWCNTs | Showed no cytotoxic effects | Intracellular delivery of oligonucleotide molecules | Human macrophages | Cellot et al., 2009 [58] |
Amine-terminated CNTs
| Cross cellular membrane without cytotoxicity | Delivery of amino acids, peptides, nucleic acids, or drugs | | Webster et al., 2013 [59] Shein et al., 2009 [60] He and Dai, 2004 [61] |
SWCNT-PL-PEG | Gene silencing with no apparent cytotoxic effects | SH-small interfering RNA delivery | Human T cells | Modi et al., 2010 [2] |
SWCNT-PEG-drug | Decreased reactive oxygen species mediated toxicological response and exhibited less cytotoxicity | Drug delivery | Neuronal PC12 cells | Grossman and Broderick, 2013 [10] |
SWCNT-PEG-cisplatin/doxorubicin | Remarkable reduction of cytotoxicity | Drug delivery and imaging tool | Human cancer cells/mice | Sharma et al., 2013 [62]; Ansari et al., 2011 [19] |
SWCNT-PEG-mAb (αvβ3) | Without harming adjacent normal cells | Cancer-cell targeting | αvβ3-positive U87MG cells | Tan et al., 2012 [63] |
SWCNT-PEG | Revealed no evidence of toxicity over 4 months | Mice | | Kotchey et al., 2013 [64] |
MWNT-CS-(PC) | Chitosan and PC reduced the cytotoxic effects on normal cells with specific photo-induced toxicity towards malignant cells | Photothermal therapy | MCF-7, HepG2, L-O2 cell lines | John et al., 2015 [65] |
Polyoxyethylene sorbitan monooleate (PS80) CNTs | Suppressed cytotoxicity | | Human lung mesothelium cells (MSTO-211-H) | Zheng et al., 2003 [50] |
HMDA-SWCNTs; PDDA chloride-SWCNTs | Negligible cytotoxic effects | Intracellular delivery of negatively charged biomolecules | Rat heart cells | Pardridge, 2012 [66] |
SWCNTs with human serum proteins | Blood proteins altered SWCNT cellular interaction pathways and reduced cytotoxicity | Biological applications | Human acute monocytic leukemia cell lines and human umbilical vein endothelial cells | Ciccone et al., 2011 [16] |
BSA-dispersed SWCNTs | No acute deleterious cellular effects | | Human mesenchymal stem cells and HeLa cells | Ben-Jacob and Hanein, 2008 [67] |
Albumin-SWCNTs | Induced cyclooxygenase-2 and modulating toxicity effects of SWCNTs | | RAW264.7 macrophage cell lines | Malarkey et al., 2009 [68] |
DNA-encased MWCNTs | Does not exert cytotoxic effect on lymphocytes | Selective thermal ablation of malignant tissue in vivo | In vivo | Vidu et al., 2014 [69] |
Lectin-functionalized CNTs | Increase in cell viability without signs of apoptosis | Nanovaccine fabrication | J774A macrophage (MOs) cell line | Kesharwani et al., 2012 [70] |
Fluorescent CNT-FITC/biotin conjugates | Reduced cytotoxicity | Delivery systems | HL60 cells | Nho et al., 2010 [71] |
Cationic fCNTs | Lowered cytotoxicity in vitro | Delivery of drugs and biomolecules | CHO, 3T3 fibroblast, Jurkat, HL60 cell lines | Kim et al., 2012 [72] |
|